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Enterohemorrhagic Escherichia coli (EHEC) O157:H7 is a diarrheal pathogen that causes attaching and
effacing (A/E) lesions on intestinal epithelial cells. Strains of the O157 serogroup carry the large virulence
plasmid pO157, which encodes the etp type II secretion system that secretes the genetically linked zinc
metalloprotease StcE. The Ler regulator controls expression of many genes involved in A/E lesion formation,
as well as StcE, suggesting StcE may be important at a similar time during colonization. Our laboratory has
previously demonstrated that StcE cleaves C1-esterase inhibitor, a regulator of multiple inflammation path-
ways. Here we report two new substrates for StcE, mucin 7 and glycoprotein 340, and that purified StcE reduces
the viscosity of human saliva. We tested the hypothesis that StcE contributes to intimate adherence of EHEC
to host cells by cleavage of glycoproteins from the cell surface. The fluorescent actin stain (FAS) test was used
to observe the intimate adherence represented by fluorescently stained bacteria colocalized with regions of
bundled actin formed on HEp-2 cells. An E. coli O157:H7 strain with a stcE gene deletion was not affected in
its ability to generally adhere to HEp-2 cells, but it did score threefold lower on the FAS test than wild-type or
complemented strains. Addition of exogenous recombinant StcE increased intimate adherence of the mutant
to wild-type levels. Thus, StcE may help block host clearance of E. coli O157:H7 by destruction of some classes
of glycoproteins, and it contributes to intimate adherence of E. coli O157:H7 to the HEp-2 cell surface.
Enterohemorrhagic Escherichia coli (EHEC) strains are
food-borne human pathogens with an infectious dose of ap-
proximately 100 CFU (56). These bacteria colonize the colon,
where they cause painful diarrhea that frequently becomes
bloody. The disease may progress to hemolytic uremic syn-
drome and death.
During the course of an infection, EHEC must evade or
overcome several of the body’s defense mechanisms. In the
oral cavity EHEC encounters saliva, one of the host’s first
defenses. Saliva provides a physical barrier to protect the oral
epithelium and contains mucins, soluble immunoglobulin A,
and proteins that can aggregate pathogens like EHEC. Phago-
cytic cells such as macrophages and neutrophils can then in-
teract with and engulf these bacteria-protein aggregates as well
as individual bacteria (35, 63). EHEC cells that make it
through the oral cavity to the stomach are confronted with
extremely low pH, which is deadly to many bacteria. EHEC,
however, is remarkable for its ability to tolerate this acidity
with little loss of viability (3, 6, 12). After the stomach, EHEC
enters the small and large intestines, where pH levels progres-
sively rise and provide an amenable environment for growth.
Typically, EHEC colonizes the colon, where there is intense
competition for space and resources from 1013 bacteria repre-
senting over 400 species (7). There, EHEC must not only
survive but also penetrate the mucus layer of the intestinal
epithelium to adhere intimately to host cells by forming attach-
ing and effacing (A/E) lesions, thus establishing an infection.
The remarkably low infectious dose suggests the bacterium
possesses traits to overcome multiple host innate defenses.
Some of the mechanisms that EHEC uses to establish an
infection, such as acid tolerance and A/E formation, are being
actively investigated and understood in increasing detail. Other
mechanisms, such as the ability to evade oral defenses, traverse
a thick mucus barrier, and successfully grow in a highly com-
petitive microbial environment, are not known.
The A/E lesion results in intimate adherence of EHEC to
the host cell membrane and a rearrangement of host cell actin
microvilli (reviewed in references 29 and 56). The bacterium
uses a type III secretion system (T3SS) to inject a bacterium-
encoded protein, Tir, into the host cell, where it is displayed on
the host cell surface (40). Tir is the primary bacterial receptor
and is bound by the intimin adhesin on the bacterial surface
(36, 37). Tir and other T3SS proteins rearrange host cell actin,
leading to effacement of the microvilli. The actin is bundled
and pushes the bacterium up above the host cell surface, cre-
ating a pedestal structure. The locus of enterocyte effacement
(LEE) element encodes intimin, Tir, the T3SS, and other pro-
teins necessary for pedestal formation (49).
E. coli O157:H7 carries a 92-kb virulence plasmid, pO157,
which encodes a number of potential virulence factors (13).
One of these genes encodes StcE, a zinc metalloprotease that
our laboratory showed is secreted by the closely linked etp type
II secretion system on pO157. Expression of the stcE gene is
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up-regulated by the global regulator Ler, which is encoded on
the chromosomal LEE element and regulates four of the five
LEE operons (45, 51).
Our laboratory has demonstrated that StcE is not a general
protease but has only one identified substrate, C1-esterase
inhibitor (C1-INH). C1-INH is a serine protease inhibitor (ser-
pin) and regulator of the complement system and other mech-
anisms of inflammation (14). Interestingly, StcE-cleaved C1-
INH retains functional serpin activity to inhibit the classical
complement cascade (43). Furthermore, StcE binds and local-
izes functional C1-INH to cell membranes, effectively enhanc-
ing the ability of C1-INH to regulate complement effectors at
sites of potential lytic complex formation. Thus, our model of
the StcE–C1-INH interaction is that StcE potentiates C1-INH
activity to reduce inflammation and complement-mediated ly-
sis at the site of infection (43). This activity would be especially
important when Shiga-like toxins and other EHEC effectors
compromise the intestinal barrier, resulting in the entry of
blood and complement proteins to the intestinal lumen.
Here we identify two additional substrates for StcE activity,
glycoprotein 340 (gp340) and mucin 7 (MUC7), and report
that StcE reduces the viscosity of human saliva. The substrates
are heavily glycosylated proteins with defensive roles found in
saliva and other tissues (10, 35, 53). The mucinase activity of
StcE and the fact that its expression is coregulated with the
pedestal-forming proteins of the LEE element led us to the
hypothesis that StcE contributes to intimate adherence of E.
coli O157:H7 to host cells by degrading the protective layer of
mucins and glycoproteins on the host cells. Herein we provide
evidence to support this hypothesis and a role for StcE in
establishing E. coli O157:H7 infection by helping the bacte-
rium evade the mucosal defenses of the host. A model that
reconciles the mucinase activity of StcE with its C1-INH cleav-
ing activity is presented.
MATERIALS AND METHODS
Strains and media. For all cloning steps, bacteria were grown using Luria-
Bertani broth or plates (Fisher Scientific, Pittsburgh, Pa.). Strains used were
EDL933, a model strain for EHEC pathogenesis isolated from ground beef (61);
WAM2871, E. coli carrying the helper plasmid pUX-BF13 encoding Tn7 trans-
posase genes tnsABCDE (21); and WAM1301, the E. coli S17pir host strain.
Strain construction. An EDL933 stcE deletion mutant was constructed by the
linear recombination ( Red) method of Datsenko and Wanner (20). Briefly, the
oligonucleotides 5 707 (5-ATG AAA TTA AAG TAT CTG TCA TGT ACG
ATC CTT GCC CCT TGT GTA GGC TGG AGC TGC TTC-3) and 3 708
(5-TAA TTT ATA TAC AAC CCT CAT TGA CCT AGG TTT ACT GAA
GCA TAT GAA TAT CCT CCT TAG-3) were used to amplify by PCR the
chloramphenicol resistance cassette from the nonpolar (in frame, with added
ribosome binding site) plasmid template pKD3. The resulting product was then
transformed by electroporation into WAM2806 (EDL933 carrying pKD46,
grown at 30°C in the presence of 10 mM arabinose). Integrates cured of pKD46
and lacking the stcE coding sequence were selected by growth on LB agar
containing chloramphenicol (20 g/ml) at 42°C, and mutations were confirmed
by PCR. More than 95% of the coding sequence of stcE was deleted, leaving
behind the 5 and 3 ends of the gene encoded by the oligonucleotides. The strain
was designated WAM2815.
A strain having the stcE gene complemented was created using a Tn7 trans-
posase system (21). The stcE gene was amplified from purified pO157 template
by PCR using primers 5 1135 (5-AAG GGC CCC TCT GAG GTG TCT GTT
AAA CCC GTG G-3) and 3 1136 (5-AAA AA TGG CCA CGA AGT GGC
CGC ACC GTC TCA GG-3). The gene was inserted into the ApaI-MscI sites
of pEVS107 and transformed by electroporation into the donor strain
WAM1301, creating a strain called WAM2980. The strains WAM2980 and
WAM2871 were conjugated with WAM2815. This resulted in strain WAM2997,
which is the WAM2815 stcE::cm strain that carries a single copy of stcE on the
chromosome at the glmS Tn7att site and has restored StcE expression (data not
shown).
Production of rStcE. Recombinant StcE protein was created using the
IMPACT protein expression system from New England Biolabs (NEB; Beverly,
Mass.). Briefly, nucleotides 23121 to 25712 of the E. coli O157:H7 plasmid
pO157 (accession number AF074613) were amplified by PCR using Deep Vent
polymerase (NEB) and purified pO157 plasmid DNA as a template. This se-
quence encodes the secreted form of StcE that lacks the signal peptide, called
StcE (accession number AY714880). The gene was then ligated into pTYB1
(NEB) at the NheI and SapI restriction sites of the multiple cloning site, creating
pTEG11. This plasmid contains a fusion gene of stcE with sequences encoding a
chitin binding domain and an intein protease. The plasmid was transformed into
the E. coli expression strain ER2566 (NEB). The chitin binding domain of the
expressed protein allowed affinity purification on a chitin column, while the
intein protease allowed the target protein to be released from the two fusion
domains. The recombinant StcE (rStcE) protein has three extra N-terminal
residues (Met-Ala-Ser) but is otherwise identical to the protein sequence se-
creted by strains carrying pO157.
Identification of proteins cleaved by StcE. Whole human saliva was collected
from an investigator, and samples (20 l) were treated with rStcE (1 g) or
untreated for 2 h at room temperature. Proteins were boiled in sample buffer and
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE; 8% acrylamide) and stained with Coomassie R-250. Two proteins of
interest (approximately 300 and 150 kDa) were excised from the gel, digested
with trypsin, and analyzed by matrix-assisted laser desorption ionization–time-
of-flight spectrometry at the UW Biotechnology Center Proteomics/Mass Spec-
trometry Facility. Peptide masses were compared to those in the MASCOT
database (www.MatrixScience.com) for identification. The results for the 150-
kDa protein did not suggest a protein identification, though review of the liter-
ature for saliva proteins of similar size did suggest probable identities. The
identities were confirmed by immunoblotting with a monoclonal antibody against
gp340 (mouse anti-human; 1:10,000; MBL, Woburn, Mass.) and polyclonal
MUC7 antiserum (mouse anti-human; 1:1000; kind gift of J. G. M. Bolscher).
Other substrates tested included lactoferrin, porcine gastric mucin, bovine fetuin,
bovine submaxillary mucin, and ovalbumin, all purchased from Sigma.
Viscosity determinations. Whole human saliva was collected from an investi-
gator, cleared by centrifuging for 30 min at 12,000 g at 4°C, and split into 10-ml
samples. The viscometer and samples were equilibrated at 37°C prior to treat-
ment and measurement. The viscosity of the samples was measured before and
after a 3-h treatment with rStcE (70 g) or buffer (20 mM Tris, pH 7.5). Both
the treatment and measurements took place at 37°C. Relative viscosity was
assessed by measuring elution time in a Cannon-Fenske routine viscometer
(range, 0.5 to 4 cP; Cannon Instrument Company, State College, Pa.). The
elution time for water was considered 0% viscosity, while buffer-treated saliva
was considered 100%. Two to four measurements were taken per time point, and
the experiment was repeated three times.
Tissue culture. HEp-2 cells were maintained in Eagle’s modified minimum
essential medium (Mediatech, Herndon, Va.) supplemented with 10% fetal
bovine serum (Atlanta Biologicals, Norcross, Ga.), 10 mM sodium pyruvate,
penicillin, streptomycin, and amphotericin B. After achieving confluence, cells
were passaged by lifting with 0.25% trypsin–EDTA (Mediatech) and diluted to
1:5 or 1:10.
Biotinylation experiments. Proteins on HEp-2 cell surfaces were biotinylated
on carboxyl and aldehyde groups by using biotin hydrazide with 1-ethyl-3(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) according to the man-
ufacturer’s protocol (Pierce, Rockford, Ill.). Cells were then incubated in phos-
phate-buffered saline (PBS) or PBS plus rStcE (5 g/ml) at 37°C. After 2 h the
samples were separated into supernatant and two detergent-soluble cell fractions
(2% saponin–PBS and 0.5% digitonin–saponin–PBS). The biotinylated proteins
were captured using NeutrAvidin immobilized on beads (Pierce). Beads from
each fraction were then washed, boiled in sample buffer, and separated on both
an 8% acrylamide gel and a 1% agarose gel. Proteins were blotted to nitrocel-
lulose and probed with streptavidin-horseradish peroxidase (Kirkegaard & Perry
Laboratories, Gaithersburg, Md.). The blot was then visualized by exposure to
Hyperfilm (Amersham Biosciences Corp., Piscataway, N.J.).
Fluorescent actin staining (FAS). An adaptation of methods described by
Knutton et al. (41) and Donnenberg and Nataro (23) was employed. HEp-2 cells
were grown in eight-well slides (Nalge Nunc International, Naperville, Ill.) for 24
to 48 h (50 to 80% confluent). Cells were washed three times in PBS to remove
any residual antibiotics on the medium. Bacterial strains were inoculated from a
single colony on an LB plate into Lennox broth (46) and grown to stationary
phase (12 to 18 h) at 37°C without shaking. All strains grew to similar densities
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(CFU per milliliter). The medium used for infection was Dulbecco’s modified
minimum essential medium supplemented as above but without antibiotics. The
overnight bacterial culture was diluted 1:25 in this medium for an average
inoculation of 8  106 CFU/ml. The medium-bacteria mixture (0.25 ml) was
placed on the cells and incubated at 37°C for a total of 6 to 7 h. The medium was
removed at midpoint of incubation and replaced with fresh medium with no
additional bacteria.
After infection, cells were washed thoroughly (five to six times) with PBS and
fixed with paraformaldehyde (3% for 10 min). Cells were washed with PBS (three
times for 3 min) after fixation. A 15-min blocking step with antibody dilution
solution (2% bovine serum albumin, 0.1% Triton X-100 in PBS) was used to
inhibit nonspecific staining. Bacteria were treated with a monoclonal antibody
(1:200; 30 min) specific for the O157 O-antigen (U.S. Biologicals, Swampscott,
Mass.). After washing in PBS, cells were stained with the secondary antibody
solution containing goat anti-rabbit antibody conjugated to Alexa 488 (1:1,000;
Molecular Probes) and the actin-staining fungal toxin phalloidin, conjugated to
Alexa 594 (1:400, Molecular Probes).
Samples were analyzed using a Zeiss fluorescence microscope and a 40 plan
apochromat numerical aperture 1.3 objective (Carl Zeiss MicroImaging Inc.,
Thornwood, N.Y.). Images were acquired with an Axiocam monochrome charge-
coupled device camera (Zeiss) and OpenLab software (Improvision, Lexington,
Mass.). Samples were blindly coded to prevent potential bias. Random fields
from sample wells were selected out of focus on the phalloidin channel such that
no actin bundles were discernible that might bias field selection. Approximately
10 fields of each sample were imaged, and the number of foci that had bundled
actin were counted. Foci were defined as either a single bacterium or a cluster of
bacteria separated from other foci by more than the length of a bacterium. The
experiment was repeated five times with similar results.
Statistical methods. The means of the viscosity determinations (n  4 mea-
surements per sample) were compared using the Student t test. FAS data from
the five experiments were combined and analyzed using a one-way analysis of
variance test to determine if all the means were equal. A Dunnett’s posttest was
then used to compare the means of different samples to that of the control
(EDL933) and to determine P values. Numbers of fields observed for each
sample were as follows: EDL933 (n  54), EDL933 plus rStcE (n  34),
WAM2815 (n  68), WAM2815 plus rStcE (n  58), WAM2997 (n  33).
Nucleotide sequence accession numbers. The sequence for the secreted form
of StcE has been deposited in the GenBank database under accession number
AY714880. The pO157 plasmid is available in GenBank under accession number
AF074613.
RESULTS
StcE cleaves gp340 and MUC7. The only previously known
substrate for the StcE protease was C1-INH (45). We hypoth-
esized that saliva would provide a potential source of sub-
strates, as it is the first host tissue that EHEC encounters. The
rStcE protease was incubated with whole human saliva, and
the proteins were separated by SDS-PAGE. The results (Fig.
1A) demonstrated that the migration of two Coomassie-
stained, large-molecular-weight protein bands changed as a
result of rStcE treatment. Treatment with a proteolytically
inactive rStcEmutant (45) did not cause this migration change
(data not shown). The larger protein (300 kDa) was identi-
fied by mass spectrometry as gp340, a common salivary protein
that is encoded by an alternately spliced variant of the gene
DMBT1 (deleted in malignant brain tumors 1). The smaller
protein did not yield useful mass spectrometry data but, based
on the literature and its size (72), was surmised to be MUC7.
Both proteins were positively identified as substrates in immu-
noblot assays with antiserum to MUC7 (Fig. 1B) and antibody
to gp340 (Fig. 1C).
StcE reduces the viscosity of saliva. Heavily glycosylated
proteins such as gp340, MUC7, and other mucins and glycop-
roteins are largely responsible for the viscosity of mucous ma-
terial such as saliva. We hypothesized that StcE cleavage of
these proteins may result in reduced viscosity of saliva. This
hypothesis was tested using a Cannon-Fenske viscometer,
where flow rate through a capillary tube measures relative
viscosity. Addition of rStcE caused a 66% reduction in viscos-
ity of saliva compared to that of water (data not shown). This
difference was statistically significant (P 	 0.0001), and the
experiment was repeated three times with similar results.
StcE does not cleave all glycosylated proteins tested. StcE
activity against lactoferrin, ovalbumin, bovine submaxillary
mucin, bovine fetuin, and porcine gastric mucin was tested
(data not shown). The results demonstrated that StcE did not
cleave these proteins.
StcE alters HEp-2 cell surface proteins. The finding that
StcE could cleave two known mucin-like proteins and reduce
viscosity of a glycoprotein-containing material led to the hy-
pothesis that StcE may cleave mucin-like proteins from the
surfaces of host cells. To test this hypothesis, we biotinylated
HEp-2 cells with biotin-hydrazide and EDC. This treatment
labels surface proteins via cross-linking to carboxyl and alde-
hyde groups. Supernatants (S1) of untreated or StcE-treated
cells contained secreted proteins or proteins cleaved from cells
by StcE. The detergent-soluble fractions (S2 and S3) contained
cell-associated proteins. Cell surface-associated proteins were
biotinylated and were captured using NeutrAvidin beads.
Analysis of samples separated by SDS-PAGE and blotted
showed that supernatants from rStcE-treated cells contained
additional bands not present in the untreated sample, and the
cell-associated fractions contained two bands that were re-
duced or missing in the rStcE-treated samples (Fig. 2A). The
biotinylated rStcE-treated samples were separated on an aga-
rose gel in order to observe larger-molecular-weight proteins,
such as mucins. The blot of the agarose gel showed similar
results (Fig. 2B) to those seen in Fig. 2A, where bands in the
FIG. 1. Whole human saliva proteins were untreated or StcE
treated and separated by SDS-PAGE. (A) Coomassie-stained gel. Two
large-molecular-weight protein bands that changed as a result of
rStcE treatment are indicated by arrowheads. (B and C) Immunoblots
probed with antiserum against MUC7 (B) and antibody against gp340
(C). Lanes in all three panels: 1, rStcE; 2, untreated saliva; 3, rStcE-
treated saliva.
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S2 and S3 fractions disappeared after rStcE treatment. At-
tempts to identify the proteins in these bands by mass spec-
trometry and immunoblotting with antiserum to MUC7 or
antibody to gp340 were unsuccessful (data not shown).
StcE contributes to intimate adherence. The demonstration
that StcE cleaves large proteins from host cell surfaces sug-
gested that StcE might play a role in adherence of E. coli
O157:H7 to host cells. We tested this by measuring viable CFU
adhering to HEp-2 cells after 3 or 6 h of infection. The results
indicated that general adherence of wild-type EDL933 or an
isogenic stcE deletion mutant (WAM2815) was the same (data
not shown). We then tested if StcE contributed to intimate
adherence of the bacterium to host cells. We used the FAS test
(23, 41) to measure the number of bacterial foci that formed
actin bundles on HEp-2 cells, the prototypic cell line for such
experiments. We found that the stcE deletion strain WAM2815
scored threefold lower on the FAS test than the isogenic wild-
type strain or the stcE-complemented strain, WAM2997, after
a 6-h infection (Fig. 3). In addition to genetic complementa-
tion, addition of rStcE protein at the beginning of the infec-
tion could abolish the stcE deficiency of the WAM2815 strain.
The FAS experiments also concurred with previous experi-
ments suggesting that StcE did not contribute to general ad-
herence. The important finding was the difference in intimate
adherence, a step thought to be important in establishing col-
onization.
DISCUSSION
Our laboratory previously showed that E. coli O157:H7
strain EDL933 secretes StcE, an extracellular zinc metallopro-
tease. In our initial studies (45), StcE did not behave as a
general protease active against many common protein sub-
strates but appeared to only cleave the complement regulator,
C1-INH. In further studies, proteins from cell lysates (HEp-2,
Caco-2, and LS174T cells) treated with StcE that were sepa-
rated by SDS-PAGE and stained with Coomassie blue showed
no bands that shifted or decreased in intensity. In this study,
however, we identified two salivary glycoproteins, gp340 and
MUC7, as substrates for StcE proteolysis. We additionally
showed that purified rStcE reduces the viscosity of human
saliva by 66%, probably the result of this StcE mucinase activ-
ity. We propose that StcE may contribute to the low infectious
dose of E. coli O157:H7 by preventing the formation of mucin-
bacteria aggregates that could lead to bacterial elimination in
mucosal environments such as the oral cavity. Furthermore, we
demonstrate that StcE degrades several large cell surface pro-
teins on HEp-2 cells. Coincident with or because of this activ-
ity, E. coli O157:H7 expressing StcE has an increased ability to
carry out intimate adherence with HEp-2 cells as measured by
FAS. Our model (Fig. 4) suggests that StcE mediates increased
intimate adherence by reducing the mucous glycocalyx cell
surface barrier, allowing a closer interaction between the bac-
terium and host cell. In the colon, StcE cleavage of mucins and
glycocalyx matrix could also lead to a reduction of commensal
bacteria in the immediate area, thereby enhancing the ability
of E. coli O157:H7 to compete for space and nutrients.
We recently demonstrated that StcE interaction with C1-
INH surprisingly potentiates rather than destroys C1-INH reg-
ulation of classical complement activation. StcE binds to bac-
terial or host cell surfaces and then localizes active C1-INH,
which subsequently reduces complement-mediated lysis of
both bacteria and host cells (43). Therefore, we believe the
mucinase activity of StcE is important in early stages of colo-
nization, while the StcE-mediated potentiation of C1-INH ac-
tivity may be important during the bloody colitis phase of E.
coli O157:H7 disease. At this stage it is hypothesized that
Shiga-like toxins and other effectors compromise the intestinal
epithelial barrier and damage the intestinal endothelium,
which results in entry of blood and serum effectors into the
intestinal lumen (56). As a corollary to the bifunctional model
of StcE activity, we hypothesize that the kinetics and binding of
FIG. 2. Blots of biotinylated proteins of buffer- or StcE-treated
HEp-2 cells. HEp-2 cell surface proteins were labeled with biotin,
treated with buffer or rStcE, and then harvested in three fractions: S1,
proteins collected in supernatant; S2, cellular proteins soluble in 2%
saponin; S3, cellular proteins soluble in 0.5% digitonin and 2% sapo-
nin. Fractioned proteins were separated by SDS-PAGE (A) or by
SDS-agarose gel (B) and blotted to nitrocellulose. Streptavidin-horse-
radish peroxidase was used to detect biotinylated proteins. Lanes 1 and
2, S1 proteins from buffer- and StcE-treated cells; lanes 3 and 4, S2
proteins from buffer- and StcE-treated cells; lanes 5 and 6, S3 proteins
from buffer- and StcE-treated cells. Arrowheads in panel A indicate
bands in cell-associated fractions that were reduced or missing in the
rStcE-treated samples. Brackets in panel B indicate S2 and S3 frac-
tions that disappeared after rStcE treatment.
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StcE to the different substrates (e.g., C1-INH versus mucins)
are different. These studies are currently under way in our lab.
Both saliva and intestinal mucus are composed of heavily
glycosylated proteins, including the proteins of the mucin fam-
ily. The structure of the mucins is characterized by a central
region composed of tandem repeats that are serine/threonine
rich and heavily glycosylated (55). The result is a protein with
a “bottle-brush” conformation that can be 50 to 200 nm long
and have molecular masses of hundreds to thousands of kilo-
daltons (68). Mucins can be cell bound or secreted and provide
lubrication in the gastrointestinal tract. A firm, tightly adherent
mucus layer over mucosal cells is 100 m thick, while the
loosely adherent mucus layer can be several times thicker (18,
66). Secreted mucins are gel forming, in part because they can
form chains of disulfide-linked monomers. They also function
to protect the single cell layer of the intestinal epithelium from
the “outside world” of food and microorganisms constantly
flowing through the intestine. The mucus layer is impermeable
to large molecules but permeable to ions, sugars, nutrients, and
other small molecules (68).
The emerging picture of StcE protein substrates is that they
are heavily glycosylated, mostly via O-linkages, and that these
FIG. 3. Immunofluorescent images of HEp-2 cells infected by strains of E. coli O157:H7. HEp-2 cells were infected for 6 h with strains EDL933,
WAM2815, and WAM2997, either with or without 2 g of StcE. (A) Samples were stained for actin (red) and bacteria (green). Images are
representative of data shown in panel B. (B) Actin-bundling foci were enumerated in sample fields for each infection. EDL933, wild-type EHEC;
WAM2815, stcE:cat; WAM2997, WAM2815 complemented with the stcE gene. Data shown are the means and standard errors of the means of
the combined results from five independent experiments. *, only the mean of sample WAM2815 was significantly different from the mean of the
control, EDL933, based on the Dunnett posttest (P 	 0.001).
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regions contain repeated amino acid sequences. The previously
identified StcE substrate, C1-INH, shares these features with
MUC7 and gp340. C1-INH has a highly conserved C-terminal
serpin domain, but in contrast to other serpins, it has a unique
120-amino-acid N terminus that is heavily glycosylated. One
region of the N terminus (residues 67 to 97) contains a series
of imperfect repeats of the sequence Glx-Pro-Thr-Thr (11, 19).
Recent results in our laboratory indicate that the C1-INH
cleavage site for StcE lies between the N terminus and serpin
domain, probably just C terminal to the glycosylated region
and repeats (43). This suggests that other StcE substrates are
likely to also contain repeated sequences and multiple O-gly-
cosylations. It should be noted, however, that StcE is not a
general mucinase because it does not cleave all glycosylated
proteins, as evidenced by our inability to detect cleavage of
gelatin (45), porcine gastric mucin, bovine submaxillary mucin,
bovine fetuin, lactoferrin, or ovalbumin (data not shown).
Other enteropathogens produce proteins with mucinase ac-
tivity. For instance, the HA/P zinc metalloprotease of Vibrio
cholerae and the Pic protease of Shigella flexneri and enteroag-
gregative E. coli have both been shown to have mucinase ac-
tivity. In both cases, however, the proteases are active against
a wide variety of proteins. HA/P degrades fibronectin, ovomu-
cin, and lactoferrin and is 61% identical to Pseudomonas
aeruginosa elastase, another broad-spectrum protease (27, 32).
In infections, HA/P has been suggested to be a factor mediat-
ing adherence as well as detachment (4, 5, 26). Pic is an auto-
transported serine protease that cleaves mucins from murine
and bovine sources, including gelatin (33). Thus, in the class of
enteropathogen mucinases, StcE seems unique in that it seems
to have a more limited set of substrates.
MUC7 (also called MG2), one of the StcE substrates iden-
tified here, is found at high levels in saliva (100 to 980 g/ml)
as well as in lung secretions and tears. It has six repeats of 23
residues, 9 of which are possible glycosylation sites (10, 67). It
binds a variety of bacteria, complexes with soluble immuno-
globulin A and lactoferrin, and has antifungal activity (47, 63,
64). Roughly 70% of its molecular weight is composed of
posttranslational modifications in the form of glycosylations
(62).
The other substrate identified here, gp340, is one of at least
two proteins resulting from alternative splicing of transcripts
from the DMBT1 gene (34, 53, 65). Known DMBT1 proteins
include DMBT1 and gp340 (previously identified as salivary
agglutinin). They are members of the scavenger receptor cys-
teine-rich (SRCR) family and are primarily composed of 14
nearly identical SRCR domains. These are separated by
SRCR-interspersed domains, which contain many potential
O-glycosylation sites. On either side of the 13th SRCR domain
lie two CUB (C1r/C1s Uegf Bmp1) domains. After the 14th
SRCR domain is a ZP (zona pellucida) domain (9, 54). Each of
these domain types is thought to mediate protein-protein in-
teractions. gp340/DMBT1 have characteristics of a pattern-
recognition receptor and bind the collectins SP-D and SP-A,
which are also known to aggregate bacteria and are involved in
mucosal inflammation responses (35, 65, 69). A peptide de-
rived from one of the gp340/DMBT1 SRCR domains binds a
wide variety of bacteria, including E. coli (9). This activity is
thought to mediate clearance of pathogens from mucosal en-
vironments through creation of protein-bacteria aggregates
and interactions with phagocytic cells (38).
Together, MUC7 and gp340 have been described to have
important roles in innate oral defense mechanisms. Although
the bacterium may not reside in the oral cavity for long periods
of time, mastication mixes food with saliva proteins, which are
all swallowed together and interact during initial digestion.
MUC7 and gp340, as well as unknown StcE substrates, may be
present throughout the mucus layers of the gastrointestinal
tract.
Both mass spectrometry and immunoblotting with antiserum
against MUC7 and a monoclonal antibody against gp340 failed
to identify any proteins in samples of untreated or StcE-treated
FIG. 4. Model for contribution of StcE to intimate adherence of E. coli O157:H7 to host cells. The StcE protease cleaves heavily glycosylated
proteins of the glycocalyx and mucin layer, thereby reducing levels of competing organisms in the local environment and allowing the pathogen
to come into close proximity with the host cell membrane. Red rectangles represent EHEC and green polygons represent StcE, while the other
shapes and colors represent other microorganisms.
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HEp-2 cells (data not shown). Their identity may not be par-
ticularly important in terms of E. coli O157:H7 pathogenesis,
given that HEp-2 cells are cervical cells (16, 57, 58). However,
HEp-2 cells are the predominant model for studies of A/E
formation, and results from this model system have been cor-
related with in vivo results (8, 24, 50). Interestingly, DMBT1
gene products are produced and secreted by cells in the colon
(52, 53). Therefore, in vivo, DMBT1 gene products are likely to
be colonic mucosal proteins that StcE acts upon to promote E.
coli O157:H7 colonization and disease. In addition, DMBT1
gene products are likely to have roles in innate defense in the
colon similar to their role in the oral cavity. The cleavage of
DMBT1 gene products may also interfere with normal host
signaling or cell differentiation, since the gene encodes a vari-
ety of domains as discussed above.
Previous studies have demonstrated that the common E. coli
O157:H7 virulence plasmid, pO157, and therefore stcE, is not
required for intimate adherence (30, 39, 70). Therefore, it is
not surprising that the role of StcE in enhancing this activity
has gone unrecognized. Many studies investigating the details
of intimate adherence use enteropathogenic E. coli (EPEC)
rather than EHEC strains. In vitro, EHEC does not adhere
intimately as readily as EPEC (22). Growth under conditions
unfavorable to stcE expression may partially explain this dif-
ference.
Our laboratory has recently shown that only a subset of
EPEC strains contain the stcE gene, and the strain typically
used in A/E studies, E2348/69, does not have stcE (44). EPEC
disease is usually considered an event in the small intestine
(56), while EHEC infects the large intestine. These two envi-
ronments differ in many respects. The large intestine contains
different mucins and 2- to 3-log-higher levels of normal flora
than the small intestine (7, 18). The propensity to colonize
different sites could be due to a number of factors influenced
by characteristics of the host, the intestinal flora, and bacterial
strain. For example, an EHEC strain that expressed an EPEC-
derived intimin gene allowed EHEC to colonize tissue from a
human small intestine (28).
A recent report suggested that the three main EPEC pro-
teins involved in general adherence to differentiated Caco-2
cells were BFP, EspA, and intimin (17). BFP mediates rapid
adherence (within 10 min), EspA is responsible for a low level
of adherence under similar conditions, and intimin imparts no
adherence unless the host cells have been preinfected with a
Tir-producing strain. Among these, BFP seems to be most
important for adherence. Indeed, strains with inactivated BFP
are deficient for microcolony formation, show reduced adher-
ence to host cells, and cause less diarrhea in volunteers (8, 17,
31). However, there is a class of “atypical” EPEC strains that
lack the plasmid that encodes BFP and cause disease in adults
in industrialized countries, as opposed to infants in underde-
veloped countries, which is the typical population affected by
EPEC (2, 25, 60, 71). Interestingly, the stcE-positive EPEC
strains seem to be restricted to a group of atypical EPEC of the
O55:H7 serotype (44). Since some atypical EPEC strains lack
BFP but have stcE, it is possible that StcE helps compensate
for the deficiency of BFP-mediated adherence, possibly by
increasing the efficiency of EspA-mediated adherence. Inter-
estingly, Mack et al. recently reported that addition of mucin-
enriched medium can inhibit adherence of EPEC strain
E2348/69 to HEp-2 cells (48).
Our multifunctional model of StcE activity has precedents in
EHEC pathogenesis. For example, the Tir protein is an EHEC
receptor as well as a cytoplasmic effector that participates in
host cell signaling and actin organization (15, 29). The EspA-
composed filaments of the T3SS serve as adhesins as well as
channels for protein transport from bacterium to host cell (1,
17, 42, 59). Characterization of the functional consequences of
StcE activity on its substrates and further identification of
additional substrates will lead to a better understanding of its
role in E. coli O157:H7 pathogenesis. Furthermore, the asso-
ciation of stcE with an atypical EPEC lineage leads to a po-
tential use of stcE as an epidemiological and evolutionary
marker to describe atypical EPEC strains, which are an impor-
tant emerging class of pathogenic E. coli (2, 25, 60, 71).
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